adalimumab vs dupilumab
Side-by-side comparison of adalimumab and dupilumab. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Humira
Dupixent
Idacio is a medicine that blocks a protein called TNF. It is used to treat several diseases, including arthritis and Crohn's disease.
Dupixent is a medicine that can help treat several conditions. It works by blocking certain proteins in your body that cause inflammation.
Idacio can help adults with rheumatoid arthritis by reducing joint pain and damage. It can also help children (2 years and older) with juvenile idiopathic arthritis. Idacio treats psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis.
Dupixent can treat moderate-to-severe atopic dermatitis (eczema) in adults and children 6 months and older. It is also used for asthma in people 6 years and older, especially if they have an eosinophilic phenotype or need oral steroids. Dupixent can also treat chronic rhinosinusitis with nasal polyps in adults and children 12 years and older, eosinophilic esophagitis in adults and children 1 year and older, prurigo nodularis and chronic spontaneous urticaria in adults and children 12 years and older, chronic obstructive pulmonary disease in adults, and bullous pemphigoid in adults.
Idacio works by blocking a protein in your body called tumor necrosis factor (TNF). TNF can cause inflammation and damage in certain diseases. By blocking TNF, Idacio can reduce these symptoms.
Dupixent is a type of medicine called a monoclonal antibody. It blocks two proteins called interleukin-4 (IL-4) and interleukin-13 (IL-13). By blocking these proteins, Dupixent helps to reduce inflammation and improve your symptoms.
- • Infections (like colds or sinus infections)
- • Injection site reactions (redness, itching, pain, or swelling)
- • Headache
- • Rash
- • Injection site reactions (like redness, swelling, or pain)
- • Conjunctivitis (pink eye)
- • Blepharitis (eyelid inflammation)
- • Oral herpes (cold sores)
- • Keratitis (inflammation of the cornea)
- Pain 49,062
- Joint pain 48,041
- Pain at the injection site 47,251
- Tiredness 39,113
- Rheumatoid arthritis 35,571
- Itching 48,441
- Eczema 37,675
- Skin rash 33,431
- Pain at the injection site 30,477
- Eczema 22,304
Idacio can increase your risk of serious infections that could lead to hospitalization or death. Tell your doctor if you have any infections before starting Idacio. Idacio may also increase your risk of certain cancers, including lymphoma. Children and teens taking TNF blockers like Idacio have developed rare, aggressive cancers.
Dupixent can cause serious allergic reactions, including anaphylaxis. Stop using Dupixent and get medical help right away if you have any signs of an allergic reaction. Tell your doctor if you get new or worsening eye problems, such as conjunctivitis or keratitis. Dupixent can sometimes cause eosinophilic conditions, so watch for symptoms like a vasculitic rash, worsening lung symptoms, heart problems, kidney problems, or nerve damage. Do not stop taking steroid medicines suddenly when you start Dupixent. Talk to your doctor about how to slowly lower your steroid dose if needed. Tell your doctor if you develop new psoriasis symptoms or joint symptoms.
Tell your doctor if you are pregnant or plan to become pregnant. Idacio can cross the placenta and may affect your baby's immune system. Talk to your doctor about vaccines for your baby if you took Idacio during pregnancy.
Tell your doctor if you are pregnant or plan to become pregnant. There is a pregnancy registry to track outcomes in women who use Dupixent during pregnancy; you can enroll by calling 1-877-311-8972. It is not known if Dupixent passes into breast milk or if it could harm a nursing baby, so talk to your doctor about the best way to feed your baby if you are using Dupixent.
Also Compare, Nearby Drugs
Compare adalimumab with
How to Read This adalimumab vs dupilumab Comparison
adalimumab is classified in the TNF-Alpha Inhibitor (Biologic) drug class, while dupilumab sits within the Anti-IL-4/IL-13 Monoclonal Antibody class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, adalimumab has 219,038 submissions while dupilumab has 172,328. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between adalimumab and dupilumab - always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.